Literature DB >> 9388817

Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree.

A Silbergeld1, F Dastot, B Klinger, H Kanety, R Eshet, S Amselem, Z Laron.   

Abstract

Laron syndrome (LS) is a hereditary form of GH resistance due to molecular defects in the GH receptor (GHR). Most of the identified mutations are located in the extracellular domain of the receptor, resulting in a lack of serum GHBP in the majority of LS patients. We present an LS patient with supranormal levels of serum GHBP, in addition to 35 of her relatives. The proband is a 3.5 year-old Druse girl with severe short stature (height SDS -5.1), high GH (250 micrograms/l), low IGF-I (2.7 nmol/l) and IGFBP-3 (410 micrograms/l), both unresponsive to exogenous GH. The binding capacity of the serum GHBP was 22 nM (adult reference serum, 0.7 nM), with an affinity constant Ka = 1.9 x 10(9) M-1 comparable to that of normal sera (Ka = 1.7-2.1 x 10(9) M-1). The apparent MW of the GHBP was approximately 60-80 kDa, similar to that of control sera. In the proband's sister, parents, grandparents and uncles, extremely high GHBP values were observed (43.0 +/- 4.8 RSB, n = 10) compared with normal adults (0.81 +/- 0.06 RSB) (p << 0.001). The remaining subjects had normal or moderately elevated GHBP levels. Serum GH in adults with high GHBP was significantly elevated above control values (6.0 +/- 0.9 micrograms/l vs 0.76 +/- 0.13 microgram/l, p < 0.001). Serum IGF-I and IGFBP-3 levels were normal in all the subjects, with the exception of an aunt (IGF-I 3.9 nmol/l) and the proband's sister (IGFBP-3 460 micrograms/l). All the subjects' heights were within the normal range. Analysis of the GHR gene performed in the proband revealed an as yet undescribed homozygous intronic point mutation. It consists of a G-->T substitution at nucleotide 785-1 preceding exon 8, a sequence that encodes the transmembrane domain. This mutation, which destroys the invariant dinucleotide of the splice acceptor site, is expected to alter GHR mRNA splicing and to be responsible for skipping exon 8. The resulting truncated protein that retains GH binding activity is probably no longer anchored in the cell membrane, affecting signal transmission in the homozygous patient and causing high GHBP levels in the heterozygous relatives.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9388817     DOI: 10.1515/jpem.1997.10.3.265

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  7 in total

1.  Efficient generation of GHR knockout Bama minipig fibroblast cells using CRISPR/Cas9-mediated gene editing.

Authors:  Rui Wang; Jian-Ying Zhang; Ke-Huan Lu; Sheng-Sheng Lu; Xiang-Xing Zhu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-27       Impact factor: 2.416

2.  Transgenic Wuzhishan minipigs designed to express a dominant-negative porcine growth hormone receptor display small stature and a perturbed insulin/IGF-1 pathway.

Authors:  Feida Li; Yong Li; Huan Liu; Xingju Zhang; Chuxin Liu; Kai Tian; Lars Bolund; Hongwei Dou; Wenxian Yang; Huanming Yang; Nicklas Heine Staunstrup; Yutao Du
Journal:  Transgenic Res       Date:  2015-10-28       Impact factor: 2.788

3.  Identification of two novel mutations in the human growth hormone receptor gene.

Authors:  O Shevah; P Borrelli; M Rubinstein; Z Laron
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 4.  Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction.

Authors:  A L Rosenbloom
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

5.  Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity.

Authors:  A David; F Miraki-Moud; N J Shaw; M O Savage; A J L Clark; L A Metherell
Journal:  Eur J Endocrinol       Date:  2009-10-07       Impact factor: 6.664

6.  Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein.

Authors:  Ankur Rughani; Dongsheng Zhang; Kanimozhi Vairamani; Andrew Dauber; Vivian Hwa; Sowmya Krishnan
Journal:  Clin Endocrinol (Oxf)       Date:  2020-01-22       Impact factor: 3.478

Review 7.  Laron syndrome - A historical perspective.

Authors:  Zvi Laron; Haim Werner
Journal:  Rev Endocr Metab Disord       Date:  2020-09-22       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.